BioNTech CEO Sahin says a new vaccine will probably be needed by the middle of next year to fight off Covid variants. BioNTech (BNTX) Chief Executive Ugur Sahin says a new vaccine will ...
Conference call and webcast scheduled for May 6, 2024, at 8:00 a.m. EDT (2:00 p.m. CEST) MAINZ, Germany, May 6, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...
Moderna CEO Stéphane Bancel ... in the effectiveness of Pfizer-BioNTech versus omicron after just a few months creates new challenges." Dr. Paul Offit, a vaccine expert at the Children’s ...
Hong Kong will have another choice for a Covid-19 vaccine targeting the Omicron variant, with drug maker BioNTech offering to make its second-generation jabs available in the city as early as ...
Pfizer’s CEO Albert Bourla said ... People in Great Britain will be able to buy the latest Omicron-directed version of Pfizer/BioNTech’s COVID-19 vaccine from retail pharmacies, starting ...
Yes, the Pfizer/BioNTech and Moderna Covid-19 vaccines have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA). Yes, that’s exciting news. Yes ...
And Ugur Sahin, CEO of BioNTech, said, “These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to ...
Context: Latest one-dose BioNTech vaccine guidance for city’s adolescents Hong Kong’s adolescents aged 12 to 17 will now only need one dose of the German-made BioNTech vaccine. This comes ...
BioNTech said that with Pfizer, it delivered their Omicron XBB.a.5-adapted COVID-19 vaccine. In 2023, the companies delivered more than 400 million COVID-19 vaccine doses worldwide, down from ...
The German pharma firm BioNTech on Monday said its vaccine sales were more than tripled ... placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong ...
Looking beyond immediate vaccine sales, BioNTech is shifting its strategic focus towards its oncology pipeline, which includes early to mid-stage trial readouts throughout the year. This shift is ...